Growing Concern Over Childhood Obesity
Childhood obesity has reached alarming proportions worldwide, with the World Health Organization (WHO) now issuing a stark warning about the use of pharmaceutical interventions for the youngest patients. Recent estimates indicate that roughly 170 million children and adolescents globally live with obesity, a figure that includes 70 million youngsters aged between five and nine. The prevalence in this age bracket has surged dramatically, having quadrupled from 2 % in 1990 to 8 % today. In 2024 alone, 35 million children under the age of five were classified as overweight. These statistics underscore a public‑health crisis that is prompting urgent debate among clinicians, policymakers and families.
Why Medication May Not Be the Answer for Under‑Tens
The WHO’s latest guidance makes clear that obesity‑targeting medications such as GLP‑1 receptor agonists—commonly sold under brand names Mounjaro and Wegovy—should not be administered to children younger than ten. While most of these drugs are licensed for use in older children and adolescents, a concerning number of off‑label prescriptions are being written for much younger patients. Moreover, pharmaceutical companies are actively trialling the treatments in children as young as six, raising ethical and safety questions. Dr Luz De Rigil, Director of Nutrition and Food Safety at WHO, emphasised, “For children under 10, WHO does not recommend obesity medicines, bariatric surgery or weight‑management devices. This is a strong recommendation.” She added that such interventions might be appropriate for older children and teenagers when lifestyle measures have failed and the individual is “mentally and physically prepared” for the treatment.
The organisation stresses that the focus for this age group should remain on healthier eating habits and regular physical activity. Although WHO does not oppose clinical trials, it cautions that any study involving very young children must be rigorously designed and ethically sound. In a related statement, Laurence Grummer‑Strawn, WHO’s head of Nutrition and Food Safety Actions, warned, “We are particularly concerned in this age group, if you are starting children very early on to using a GLP‑1 or drugs like this, when does that stop? We don’t really have evidence that you can use this as a temporary treatment and then turn to something dietary later on in life. We are very cautious about jumping in without clear evidence.” The lack of long‑term data on safety, growth and developmental outcomes underpins the organisation’s reticence.
Supportive Tools and Lifestyle Strategies
WHO also highlights that digital technology can play a supportive role. Activity trackers, for instance, have shown promise in encouraging movement, while certain online games that reward physical activity can make exercise feel like play. However, the evidence base remains limited, and the organisation advises that such tools should complement—not replace—broader lifestyle changes. Parents and caregivers are encouraged to create environments that promote balanced diets, regular outdoor play and limited screen time. Community programmes that provide safe spaces for children to be active, and school‑based nutrition education, are cited as effective components of a comprehensive strategy.
Why it Matters
The WHO’s stance carries significant weight for health systems, families and future research. By discouraging the use of potent obesity drugs in children under ten, the guidance aims to protect a vulnerable population from potential unknown risks while redirecting attention to proven, low‑cost interventions such as diet and exercise. This approach also challenges pharmaceutical companies to reconsider the age groups targeted in their clinical trials and to ensure that any future approvals are grounded in robust, age‑specific data. For policymakers, the recommendation underscores the need to invest in preventive programmes that address the social determinants of health—access to nutritious food, safe recreational areas and quality education. In the long run, adhering to these guidelines could curb the escalating healthcare costs associated with obesity‑related conditions like type‑2 diabetes and cardiovascular disease, ultimately fostering healthier generations across the globe.
